Other Events ·
Eton Pharmaceuticals entered into a license agreement on July 31, 2026, to acquire U.S. rights for ASN-001 (timolol…
ETONEton Pharmaceuticals, Inc.
Eton Pharmaceuticals entered into a license agreement on July 31, 2026, to acquire U.S. rights for ASN-001 (timolol topical gel) from Auson Pharmaceuticals for treating proliferating superficial infantile hemangiomas. Eton paid a $3.0 million upfront fee and will conduct a bioavailability bridging study, targeting an NDA submission in the second half of 2027. Upon FDA approval, milestone payments range from $5 million to $10 million based on sales thresholds up to $280 million, with tiered royalties between 10% and 15%. ASN-001 showed elimination or near-elimination rates of 42-56% in Phase II/III trials. Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.